Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:292131.
doi: 10.1155/2012/292131. Epub 2012 Feb 22.

Hepatic arterial therapy with drug-eluting beads in the management of metastatic bronchogenic carcinoma to the liver: a multi-institutional registry

Heba Fouad  1 , Tiffany Metzger, Cliff Tatum, Ken Robbins, Robert C G Martin
Affiliations

Hepatic arterial therapy with drug-eluting beads in the management of metastatic bronchogenic carcinoma to the liver: a multi-institutional registry

Heba Fouad et al. J Oncol. 2012.

Abstract

Introduction. There has been limited information reported on the use of hepatic arterial therapy in liver dominant hepatic metastases arising from lung cancer. The aim of this study was to evaluate the safety and efficacy of hepatic arterial therapy in the treatment of liver dominant hepatic metastases arising from lung cancer. Methods. Thirteen patients underwent a total of 30 treatment sessions with Drug-Eluting Beads. Eight of the thirteen received only doxorubicin DEB (17 of the total treatments), and four patients received Irinotecan DEB (7 of the total treatments). Results. The planned preprocedural dosage was a median of 75 mg (range 19-200), with total hepatic dose exposure being a median of 150 mg (range 0-458), with a technical success rate of 97% in all 29 treatments. There were 4 adverse events related to treatment, but no evidence of hepatic insufficiency. Overall 6-month and 12-month response rates were 50%. After a median followup of 24 months, the median overall survival in this cohort was 14 months (range 7-48 months). Conclusion. Drug-eluting beads loaded with doxorubicin (DEBDOX) or irinotecan (DEBIRI) can be safely and effectively used in treatment of patients with liver predominant metastatic disease from lung cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Potential pretreatment DEBDOX treatment algorithm for treating liver dominant metastatic lung cancer. The timing of repeat dosing and the dose utilized may have to be modified based on angiographic findings, patient tolerance, and patient toxicity.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proceedings. 2008;83(5):584–594. - PMC - PubMed
    1. Brambilla E, Gazdar A. Pathogenesis of lung cancer signalling pathways: roadmap for therapies. European Respiratory Journal. 2009;33(6):1485–1497. - PMC - PubMed
    1. Schneider BJ. Non-small cell lung cancer staging: proposed revisions to the TNM system. Cancer Imaging. 2008;8(1):181–185. - PMC - PubMed
    1. Silvestri GA, Littenberg B, Colice GL. The clinical evaluation for detecting metastatic lung cancer: a meta- analysis. American Journal of Respiratory and Critical Care Medicine. 1995;152(1):225–230. - PubMed
    1. Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition) Chest. 2007;132(supplement 3):277S–289S. - PubMed

LinkOut - more resources